In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Almotriptan Drug Master File in Korea (Almotriptan KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Almotriptan. The MFDS reviews the Almotriptan KDMF as part of the drug registration process and uses the information provided in the Almotriptan KDMF to evaluate the safety and efficacy of the drug.
After submitting a Almotriptan KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Almotriptan API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Almotriptan suppliers with KDMF on PharmaCompass.